Navigation Links
MedApps Receives Prestigious Frost & Sullivan Award
Date:2/6/2008

SCOTTSDALE, Ariz., Feb. 6 /PRNewswire/ -- MedApps announced today that it is the proud recipient of the 2008 Frost & Sullivan North American Technology Innovation Award in the field of Wireless Point of Care.

Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

"Frost & Sullivan does not accept nominations or submissions for their Awards," said Jeff Frigstad, Global Director of Frost & Sullivan's Best Practices Awards division. "The selection of this Award comes through in-depth interviews and primary market analysis conducted by our industry analyst team."

MedApps has been recognized for its unique technologies (Body Area Network and BluePAL(TM)) forming the backbone of its Telemedicine 2.0 concept. Telemedicine 2.0 as compared to the wired technology of Telemedicine 1.0 is a wireless technology, which is designed to help those patients who suffer from one or more chronic diseases such as diabetes, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), asthma or other diseases. This new technology can help healthcare professionals monitor and react to changes in a patient's medical condition as they occur. The company's dedication toward developing this novel real-time telemedicine technology platform employing individual techniques such as Body Area Network and BluePAL(TM) has attracted considerable industry interest as the nature of commercial remote glucose monitoring still remains adynamic.

"As a team, we are very proud of receiving this award," said Kent Dicks, President / CEO of MedApps. "To be recognized by Frost & Sullivan, a leading authority in industry / market trends, is extremely satisfying knowing that we are on the right track, with the right vision, at the right point in time."

About Frost & Sullivan

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.awards.frost.com.

About MedApps

MedApps, headquartered in Scottsdale, Arizona, is a new and emerging leader in Mobile Wireless Health Monitoring -- designed to connect people with their healthcare providers, in a timely and cost effective manner. MedApps was named to the Fierce Health IT Top 10 Healthcare IT Innovators for 2007 (http://www.fiercehealthit.com/innovators/2007/medapps) and was nominated for the Governors Celebration of Innovation - Startup for 2007 (http://www.celebration-of-innovation.com/news.aspx).

http://www.medapps.net

Media Contact:

Randy Strength

MedApps, Inc.

(480) 686-5676

randy.strength@medapps.net


'/>"/>
SOURCE MedApps, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
2. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
3. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
4. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
5. Regions Hospital Receives National Quality Awards
6. Laser Energetics Receives a $550,000 Order for a Dental Laser System
7. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
8. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
9. Disabled Sacramento Woman, 110, Receives Power Wheelchair Donation from The SCOOTER Store
10. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
11. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider of ... with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device ... this platform, initializing devices and importing studies are just one-click operations. This plugin ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... is sharing bold recipes for Memorial Day entertaining that are sure to satisfy ... “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes ...
(Date:5/26/2017)... BOSTON, MA (PRWEB) , ... May 26, 2017 , ... ... Care Act (AHCA), which narrowly passed the U.S. House on May 4, would result ... would be expected under continued implementation of the 2010 Patient Protection and Affordable Care ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... week that is focusing on the Peace Agreements being discussed by President Donald Trump ... in a race to try to speed up peace talks in the continuous battle ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using ... Viewers can reconnect with America as it explores some of the best places to ... for an inventive new place for a family vacation, and have discovered hiking. Many ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
Breaking Medicine Technology: